PubMed:22851870 / 232-961 JSONTXT

{"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T2","span":{"begin":0,"end":729},"obj":"METHODS"}],"text":"Canine models with acute liver failure were introduced with intravenous administration of D-galactosamine. The animals were divided into: the HBAL treatment group (n = 8), in which the canines received a 3-h treatment of HBAL; the bioartificial liver (BAL) treatment group (n = 8), in which the canines received a 3-h treatment of BAL; the non-bioartificial liver (NBAL) treatment group (n = 8), in which the canines received a 3-h treatment of NBAL; the control group (n = 8), in which the canines received no additional treatment. Biochemical parameters and survival time were determined. Levels of xenoantibodies, RNA of porcine endogenous retrovirus (PERV) and reverse transcriptase (RT) activity in the plasma were detected."}

{"project":"Goldhamster2_Cellosaurus","denotations":[{"id":"T5","span":{"begin":164,"end":169},"obj":"CVCL_D463|Transformed_cell_line|Mus musculus"},{"id":"T6","span":{"begin":164,"end":169},"obj":"CVCL_IZ69|Spontaneously_immortalized_cell_line|Homo sapiens"},{"id":"T7","span":{"begin":202,"end":205},"obj":"CVCL_1061|Cancer_cell_line|Homo sapiens"},{"id":"T8","span":{"begin":202,"end":205},"obj":"CVCL_1Q37|Spontaneously_immortalized_cell_line|Cricetulus griseus"},{"id":"T9","span":{"begin":202,"end":205},"obj":"CVCL_5A61|Spontaneously_immortalized_cell_line|Cricetulus griseus"},{"id":"T10","span":{"begin":202,"end":205},"obj":"CVCL_G649|Hybridoma|Mus musculus"},{"id":"T11","span":{"begin":202,"end":205},"obj":"CVCL_JH29|Cancer_cell_line|Homo sapiens"},{"id":"T12","span":{"begin":202,"end":205},"obj":"CVCL_LN35|Cancer_cell_line|Homo sapiens"},{"id":"T13","span":{"begin":202,"end":205},"obj":"CVCL_ZU43|Transformed_cell_line|Homo sapiens"},{"id":"T14","span":{"begin":202,"end":203},"obj":"CVCL_6479|Finite_cell_line|Mus musculus"},{"id":"T15","span":{"begin":274,"end":279},"obj":"CVCL_D463|Transformed_cell_line|Mus musculus"},{"id":"T16","span":{"begin":274,"end":279},"obj":"CVCL_IZ69|Spontaneously_immortalized_cell_line|Homo sapiens"},{"id":"T17","span":{"begin":312,"end":315},"obj":"CVCL_1061|Cancer_cell_line|Homo sapiens"},{"id":"T18","span":{"begin":312,"end":315},"obj":"CVCL_1Q37|Spontaneously_immortalized_cell_line|Cricetulus griseus"},{"id":"T19","span":{"begin":312,"end":315},"obj":"CVCL_5A61|Spontaneously_immortalized_cell_line|Cricetulus griseus"},{"id":"T20","span":{"begin":312,"end":315},"obj":"CVCL_G649|Hybridoma|Mus musculus"},{"id":"T21","span":{"begin":312,"end":315},"obj":"CVCL_JH29|Cancer_cell_line|Homo sapiens"},{"id":"T22","span":{"begin":312,"end":315},"obj":"CVCL_LN35|Cancer_cell_line|Homo sapiens"},{"id":"T23","span":{"begin":312,"end":315},"obj":"CVCL_ZU43|Transformed_cell_line|Homo sapiens"},{"id":"T24","span":{"begin":312,"end":313},"obj":"CVCL_6479|Finite_cell_line|Mus musculus"},{"id":"T25","span":{"begin":388,"end":393},"obj":"CVCL_D463|Transformed_cell_line|Mus musculus"},{"id":"T26","span":{"begin":388,"end":393},"obj":"CVCL_IZ69|Spontaneously_immortalized_cell_line|Homo sapiens"},{"id":"T27","span":{"begin":426,"end":429},"obj":"CVCL_1061|Cancer_cell_line|Homo sapiens"},{"id":"T28","span":{"begin":426,"end":429},"obj":"CVCL_1Q37|Spontaneously_immortalized_cell_line|Cricetulus griseus"},{"id":"T29","span":{"begin":426,"end":429},"obj":"CVCL_5A61|Spontaneously_immortalized_cell_line|Cricetulus griseus"},{"id":"T30","span":{"begin":426,"end":429},"obj":"CVCL_G649|Hybridoma|Mus musculus"},{"id":"T31","span":{"begin":426,"end":429},"obj":"CVCL_JH29|Cancer_cell_line|Homo sapiens"},{"id":"T32","span":{"begin":426,"end":429},"obj":"CVCL_LN35|Cancer_cell_line|Homo sapiens"},{"id":"T33","span":{"begin":426,"end":429},"obj":"CVCL_ZU43|Transformed_cell_line|Homo sapiens"},{"id":"T34","span":{"begin":426,"end":427},"obj":"CVCL_6479|Finite_cell_line|Mus musculus"},{"id":"T35","span":{"begin":470,"end":475},"obj":"CVCL_D463|Transformed_cell_line|Mus musculus"},{"id":"T36","span":{"begin":470,"end":475},"obj":"CVCL_IZ69|Spontaneously_immortalized_cell_line|Homo sapiens"},{"id":"T37","span":{"begin":569,"end":573},"obj":"CVCL_0047|Telomerase_immortalized_cell_line|Homo sapiens"},{"id":"T38","span":{"begin":692,"end":700},"obj":"CVCL_C410|Hybridoma|Mus musculus"}],"text":"Canine models with acute liver failure were introduced with intravenous administration of D-galactosamine. The animals were divided into: the HBAL treatment group (n = 8), in which the canines received a 3-h treatment of HBAL; the bioartificial liver (BAL) treatment group (n = 8), in which the canines received a 3-h treatment of BAL; the non-bioartificial liver (NBAL) treatment group (n = 8), in which the canines received a 3-h treatment of NBAL; the control group (n = 8), in which the canines received no additional treatment. Biochemical parameters and survival time were determined. Levels of xenoantibodies, RNA of porcine endogenous retrovirus (PERV) and reverse transcriptase (RT) activity in the plasma were detected."}

{"project":"GoldHamster","denotations":[{"id":"T16","span":{"begin":0,"end":6},"obj":"UBERON:0003674"},{"id":"T17","span":{"begin":19,"end":38},"obj":"D017114"},{"id":"T18","span":{"begin":19,"end":38},"obj":"D017114"},{"id":"T19","span":{"begin":25,"end":30},"obj":"UBERON:0002107"},{"id":"T22","span":{"begin":90,"end":105},"obj":"CHEBI:144817"},{"id":"T23","span":{"begin":90,"end":105},"obj":"CHEBI:60313"},{"id":"T24","span":{"begin":90,"end":105},"obj":"CHEBI:60312"},{"id":"T25","span":{"begin":90,"end":105},"obj":"CHEBI:28328"},{"id":"T30","span":{"begin":202,"end":207},"obj":"Q6NTF7"},{"id":"T31","span":{"begin":245,"end":250},"obj":"UBERON:0002107"},{"id":"T32","span":{"begin":252,"end":255},"obj":"PR:000005317"},{"id":"T33","span":{"begin":252,"end":255},"obj":"P30122"},{"id":"T34","span":{"begin":252,"end":255},"obj":"PR:000015049"},{"id":"T35","span":{"begin":252,"end":255},"obj":"Q9PSN0"},{"id":"T36","span":{"begin":252,"end":255},"obj":"Q4LDG0"},{"id":"T37","span":{"begin":252,"end":255},"obj":"PR:P19835"},{"id":"T38","span":{"begin":252,"end":255},"obj":"Q64285"},{"id":"T39","span":{"begin":252,"end":255},"obj":"PR:000012301"},{"id":"T41","span":{"begin":252,"end":255},"obj":"PR:Q8CAS9"},{"id":"T42","span":{"begin":252,"end":255},"obj":"PR:O23530"},{"id":"T43","span":{"begin":252,"end":255},"obj":"P07882"},{"id":"T44","span":{"begin":252,"end":255},"obj":"PR:Q8IXQ6"},{"id":"T45","span":{"begin":252,"end":255},"obj":"Q9ES38"},{"id":"T46","span":{"begin":252,"end":255},"obj":"PR:Q58FX0"},{"id":"T47","span":{"begin":252,"end":255},"obj":"P19835"},{"id":"T48","span":{"begin":252,"end":255},"obj":"Q9Y2P5"},{"id":"T40","span":{"begin":252,"end":255},"obj":"CHEBI:64198"},{"id":"T49","span":{"begin":312,"end":317},"obj":"Q6NTF7"},{"id":"T50","span":{"begin":331,"end":334},"obj":"PR:000005317"},{"id":"T51","span":{"begin":331,"end":334},"obj":"P30122"},{"id":"T52","span":{"begin":331,"end":334},"obj":"PR:000015049"},{"id":"T53","span":{"begin":331,"end":334},"obj":"Q9PSN0"},{"id":"T54","span":{"begin":331,"end":334},"obj":"Q4LDG0"},{"id":"T55","span":{"begin":331,"end":334},"obj":"PR:P19835"},{"id":"T56","span":{"begin":331,"end":334},"obj":"Q64285"},{"id":"T57","span":{"begin":331,"end":334},"obj":"PR:000012301"},{"id":"T59","span":{"begin":331,"end":334},"obj":"PR:Q8CAS9"},{"id":"T60","span":{"begin":331,"end":334},"obj":"PR:O23530"},{"id":"T61","span":{"begin":331,"end":334},"obj":"P07882"},{"id":"T62","span":{"begin":331,"end":334},"obj":"PR:Q8IXQ6"},{"id":"T63","span":{"begin":331,"end":334},"obj":"Q9ES38"},{"id":"T64","span":{"begin":331,"end":334},"obj":"PR:Q58FX0"},{"id":"T65","span":{"begin":331,"end":334},"obj":"P19835"},{"id":"T66","span":{"begin":331,"end":334},"obj":"Q9Y2P5"},{"id":"T58","span":{"begin":331,"end":334},"obj":"CHEBI:64198"},{"id":"T67","span":{"begin":358,"end":363},"obj":"UBERON:0002107"},{"id":"T68","span":{"begin":426,"end":431},"obj":"Q6NTF7"},{"id":"T69","span":{"begin":601,"end":615},"obj":"D000910"},{"id":"T73","span":{"begin":617,"end":620},"obj":"SO:0000356"},{"id":"T70","span":{"begin":617,"end":620},"obj":"CHEBI:33697"},{"id":"T71","span":{"begin":617,"end":620},"obj":"D012313"},{"id":"T72","span":{"begin":617,"end":620},"obj":"GO:0005562"},{"id":"T74","span":{"begin":632,"end":653},"obj":"D020077"},{"id":"T77","span":{"begin":665,"end":672},"obj":"SO:0001031"},{"id":"T78","span":{"begin":665,"end":686},"obj":"P23072"},{"id":"T79","span":{"begin":665,"end":686},"obj":"P21329"},{"id":"T80","span":{"begin":665,"end":686},"obj":"P23071"},{"id":"T81","span":{"begin":665,"end":686},"obj":"P21328"},{"id":"T83","span":{"begin":665,"end":686},"obj":"P23070"},{"id":"T84","span":{"begin":665,"end":686},"obj":"Q9NBX4"},{"id":"T85","span":{"begin":665,"end":686},"obj":"Q95SX7"},{"id":"T82","span":{"begin":665,"end":686},"obj":"D012194"},{"id":"T91","span":{"begin":673,"end":686},"obj":"GO:0003968"},{"id":"T169","span":{"begin":673,"end":686},"obj":"GO:0003899"},{"id":"T193","span":{"begin":673,"end":686},"obj":"GO:0034062"},{"id":"T210","span":{"begin":708,"end":714},"obj":"UBERON:0001969"}],"text":"Canine models with acute liver failure were introduced with intravenous administration of D-galactosamine. The animals were divided into: the HBAL treatment group (n = 8), in which the canines received a 3-h treatment of HBAL; the bioartificial liver (BAL) treatment group (n = 8), in which the canines received a 3-h treatment of BAL; the non-bioartificial liver (NBAL) treatment group (n = 8), in which the canines received a 3-h treatment of NBAL; the control group (n = 8), in which the canines received no additional treatment. Biochemical parameters and survival time were determined. Levels of xenoantibodies, RNA of porcine endogenous retrovirus (PERV) and reverse transcriptase (RT) activity in the plasma were detected."}

{"project":"Allie","denotations":[{"id":"SS1_22851870_5_0","span":{"begin":231,"end":250},"obj":"expanded"},{"id":"SS2_22851870_5_0","span":{"begin":252,"end":255},"obj":"abbr"},{"id":"SS1_22851870_5_1","span":{"begin":340,"end":363},"obj":"expanded"},{"id":"SS2_22851870_5_1","span":{"begin":365,"end":369},"obj":"abbr"},{"id":"SS1_22851870_7_0","span":{"begin":624,"end":653},"obj":"expanded"},{"id":"SS2_22851870_7_0","span":{"begin":655,"end":659},"obj":"abbr"},{"id":"SS1_22851870_7_1","span":{"begin":665,"end":686},"obj":"expanded"},{"id":"SS2_22851870_7_1","span":{"begin":688,"end":690},"obj":"abbr"}],"relations":[{"id":"AE1_22851870_5_0","pred":"abbreviatedTo","subj":"SS1_22851870_5_0","obj":"SS2_22851870_5_0"},{"id":"AE1_22851870_5_1","pred":"abbreviatedTo","subj":"SS1_22851870_5_1","obj":"SS2_22851870_5_1"},{"id":"AE1_22851870_7_0","pred":"abbreviatedTo","subj":"SS1_22851870_7_0","obj":"SS2_22851870_7_0"},{"id":"AE1_22851870_7_1","pred":"abbreviatedTo","subj":"SS1_22851870_7_1","obj":"SS2_22851870_7_1"}],"text":"Canine models with acute liver failure were introduced with intravenous administration of D-galactosamine. The animals were divided into: the HBAL treatment group (n = 8), in which the canines received a 3-h treatment of HBAL; the bioartificial liver (BAL) treatment group (n = 8), in which the canines received a 3-h treatment of BAL; the non-bioartificial liver (NBAL) treatment group (n = 8), in which the canines received a 3-h treatment of NBAL; the control group (n = 8), in which the canines received no additional treatment. Biochemical parameters and survival time were determined. Levels of xenoantibodies, RNA of porcine endogenous retrovirus (PERV) and reverse transcriptase (RT) activity in the plasma were detected."}